Vito Lorusso - Concepedia

Author

Vito Lorusso

Also Known As

Alessio Farcomeni, Lorusso, Vito, M De Lena, Simeone Liguori, V Lorusso, V. LORUSSO, V. Lorusso, VITO LORUSSO, Vito Lorusso

204

Publications

5.1K

Citations

H-Index

124

Concepts

All Affiliations

Istituto Tumori Bari Istituti di Ricovero e Cura a Carattere Scientifico University of Bari Aldo Moro Azienda Ospedaliera Treviglio Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

About

Vito Lorusso is an author at Istituto Tumori Bari specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	36	2K
2	Health Sciences	11	12	1.2K
3	Engineering	8	8	300
4	Natural Sciences	2	2	29
5	Nursing	2	2	69

Vito Lorusso

Publications

3.8K

Citations

H-Index

Page 1

	Year	Citations
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial David Cunningham, István Láng, Eugenio Marcuello, The Lancet Oncology Elderly PatientsGastrointestinal OncologyMedicineCancer ManagementCapecitabine Versus Capecitabine	2013	642
A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy Matti Aapro, H. S. Rugo, Giada Rizzi, Annals of Oncology	2014	244
Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: Results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers Alberto Spinazzi, Vito Lorusso, Gianpaolo Pirovano, Academic Radiology Gadobenate DimeglumineHepatologyMedical ImagingMedicineLiver Physiology	1999	202
Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study M. De Lena, Vito Lorusso, Agnese Latorre, European Journal of Cancer Advanced Ovarian CancerMedicinePharmacologyGynecologyPhase Ii Study	2001	167
Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX Fortunato Ciardiello, Nicola Normanno, Erika Martinelli, Annals of Oncology Gastrointestinal OncologyCetuximab ContinuationMedicinePathologyColorectal Cancer	2016	97
Capecitabine plus oxaliplatin for the first‐line treatment of elderly patients with metastatic colorectal carcinoma Pasquale Comella, D. Natale, A. Farris, Cancer	2005	91
Radiomic Analysis in Contrast-Enhanced Spectral Mammography for Predicting Breast Cancer Histological Outcome Daniele La Forgia, Annarita Fanizzi, Francesco Campobasso, Diagnostics Breast OncologyEngineeringEstrogen ReceptorDiagnostic ImagingCancer Detection	2020	88
Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase III trial G. Frasci, Vito Lorusso, Nicola Panza, Lung Cancer OncologyElderly PatientsMedicinePhase Iii TrialClinical Trials	2001	86
Time to Progression in Metastatic Breast Cancer Patients Treated With Epirubicin Is Not Improved by the Addition of Either Cisplatin or Lonidamine: Final Results of a Phase III Study With a Factorial Design Alfredo Berruti, Raffaella Bitossi, G. Gorzegno, Journal of Clinical Oncology	2002	83
Lack of Benefit of Maintenance Paclitaxel in First-Line Chemotherapy in Metastatic Breast Cancer Alessandra Gennari, Dino Amadori, Mario De Lena, Journal of Clinical Oncology	2006	80

Page 1